Industry, FDA Outline Costs Of New MDUFA Proposals; Quality Management A Strong Focus
This article was originally published in The Gray Sheet
Executive Summary
After months of negotiations, the agency has proposed hiring new staff and making significant changes to their device review process that would cost $500 million – on top of current user fee revenues – and does not account for inflation.
You may also be interested in...
FDA, Industry Agree On Working Groups To Support User-Fee Negotiations
The agency and industry agreed to create working groups allowing subject-matter experts to delve deeper into technical details on some of the key proposals raised thus far in user-fee reauthorization talks. Areas of focus include de novo reviews, pre-submissions and personnel recruitment challenges.
CDRH Prioritizes Leveraging Real-World And Patient-Preference Data, Enhancing Quality
In its 2016-2017 strategic priorities, the device center lays out specific goals for putting more emphasis on real-world postmarket data to support regulatory decisions, making better use of patient-preference input, and enhancing quality at CDRH and in industry. Topping FDA's list: gaining access to 25 million electronic patient records with device identification from global registries, insurance claims data and electronic health records, and expanding that number to 100 million by the end of 2017 to support premarket and postmarket decisions.
New Fundings And Goals To Match Raised In Latest MDUFA IV Session
As the number of de novo applications and pre-submission consultations keep growing, FDA is proposing to institute provide new funding for these programs, among a range of additional proposals laid out in a recent closed-door negotiation. The agency's plan aligns somewhat with an industry proposal, according to meeting minutes, but there is also a lot to negotiate.